A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
SARTORIUS STED BIO operates in the Medical - Instruments & Supplies industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 3.4B | 3.4B | 3.0B | 3.0B | 3.7B | 3.4B |
| Net Income | 301M | 301M | 189M | 340M | 926M | 489M |
| EPS | $3.09 | $3.09 | $1.96 | $3.66 | $10.01 | $5.31 |
| Free Cash Flow | 784M | 784M | 881M | 810M | 645M | 828M |
| ROIC | 10.2% | 6.7% | 4.4% | 6.4% | 21.5% | 26.7% |
| Gross Margin | 45.3% | 45.3% | 43.4% | 44.5% | 52.0% | 53.8% |
| Debt/Equity | 0.00 | 0.59 | 0.68 | 1.54 | 0.60 | 0.68 |
| Dividends/Share | $0.78 | $0.78 | $0.75 | $1.56 | $1.33 | $0.80 |
| Operating Income | 595M | 595M | 400M | 488M | 1.0B | 1.0B |
| Operating Margin | 17.7% | 17.7% | 13.3% | 16.2% | 28.5% | 30.0% |
| ROE | 6.5% | 6.7% | 5.2% | 12.2% | 39.5% | 26.3% |
| Shares Outstanding | 97M | 97M | 97M | 93M | 93M | 92M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 2.2B | 3.4B | 3.7B | 3.0B | 3.0B | 3.4B | 3.4B |
| Gross Margin | 52.5% | 53.8% | 52.0% | 44.5% | 43.4% | 45.3% | 45.3% |
| R&D | -97M | -130M | -139M | -141M | -156M | -151M | -151M |
| SG&A | 707M | 942M | 1.0B | 992M | 1.1B | 1.1B | 1.1B |
| EBIT | 542M | 1.0B | 1.0B | 488M | 400M | 595M | 595M |
| Op. Margin | 24.7% | 30.0% | 28.5% | 16.2% | 13.3% | 17.7% | 17.7% |
| Net Income | 389M | 489M | 926M | 340M | 189M | 301M | 301M |
| Net Margin | 17.7% | 14.4% | 25.2% | 11.3% | 6.3% | 9.0% | 9.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | 15.9% | 26.7% | 21.5% | 6.4% | 4.4% | 6.7% | 10.2% |
| ROE | 23.2% | 26.3% | 39.5% | 12.2% | 5.2% | 6.7% | 6.5% |
| ROA | 11.9% | 12.3% | 18.5% | 4.9% | 2.2% | 3.3% | 3.3% |
| Cash Flow | |||||||
| Op. Cash Flow | 479M | 828M | 645M | 810M | 881M | 784M | 784M |
| Free Cash Flow | 479M | 828M | 645M | 810M | 881M | 784M | 784M |
| Owner Earnings | 362M | 661M | 453M | 553M | 555M | 424M | 424M |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 117M | 167M | 191M | 257M | 326M | 360M | 360M |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 117M | 167M | 191M | 257M | 326M | 360M | 360M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 36M | 74M | 122M | 144M | 72M | 76M | 76M |
| Dividend Yield | 0.1% | 0.2% | 0.4% | 0.5% | 0.3% | 0.4% | 0.4% |
| Share Buybacks | 0 | 0 | 0 | 1.4M | 2.1M | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | 882M | 1.1B | 1.5B | 4.3B | 2.2B | 2.3B | -482M |
| Cash & Equiv. | 69M | 264M | 113M | 127M | 733M | 482M | 482M |
| Long-Term Debt | N/A | N/A | N/A | N/A | 2.9B | 2.1B | 2.1B |
| Debt/Equity | 0.57 | 0.68 | 0.60 | 1.54 | 0.68 | 0.59 | 0.00 |
| Interest Coverage | 12.4 | 3.6 | 19.6 | 3.2 | 1.9 | 2.7 | 2.7 |
| Equity | 1.7B | 2.0B | 2.6B | 2.9B | 4.3B | 4.6B | 4.6B |
| Total Assets | 3.3B | 4.7B | 5.3B | 8.4B | 8.9B | 9.0B | 9.0B |
| Total Liabilities | 1.6B | 2.6B | 2.7B | 5.5B | 4.6B | 4.4B | 4.4B |
| Intangibles | N/A | N/A | N/A | N/A | 1.8B | 1.7B | 1.7B |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 352M | 494M | 669M | 519M | 867M | 33M | 33M |
| Current Assets | 1.0B | 1.7B | 1.8B | 1.5B | 1.9B | 1.6B | 1.6B |
| Current Liabilities | 652M | 1.2B | 1.1B | 1.0B | 1.0B | 1.6B | 1.6B |
| Per Share Data | |||||||
| EPS | 4.18 | 5.31 | 10.01 | 3.66 | 1.96 | 3.09 | 3.09 |
| Owner EPS | 3.89 | 7.18 | 4.90 | 5.96 | 5.73 | 4.35 | 4.35 |
| Book Value | 18.04 | 22.21 | 28.61 | 31.29 | 44.52 | 47.60 | 47.60 |
| Cash Flow/Share | 5.15 | 9.00 | 6.97 | 8.73 | 9.10 | 8.05 | 6.79 |
| Dividends/Share | 0.39 | 0.80 | 1.33 | 1.56 | 0.75 | 0.78 | 0.78 |
| Shares Out. | 93.0M | 92.1M | 92.5M | 92.8M | 96.7M | 97.3M | 97.3M |
| Valuation | |||||||
| P/E Ratio | 85.7 | 97.3 | 32.6 | 72.4 | 99.7 | 78.3 | 56.3 |
| P/FCF | 69.6 | 57.4 | 46.8 | 30.3 | 21.4 | 30.0 | 21.6 |
| EV/EBIT | 63.1 | 47.7 | 30.2 | 59.2 | 52.6 | 43.3 | 27.6 |
| Price/Book | 19.9 | 23.2 | 11.4 | 8.5 | 4.4 | 5.1 | 3.7 |
| Price/Sales | 15.2 | 14.0 | 8.2 | 8.2 | 6.3 | 7.0 | 5.0 |
| FCF Yield | 1.4% | 1.7% | 2.1% | 3.3% | 4.7% | 3.3% | 4.6% |
| Market Cap | 33.3B | 47.5B | 30.2B | 24.6B | 18.9B | 23.5B | 16.9B |
| Avg. Price | 278.84 | 489.55 | 362.44 | 282.49 | 218.29 | 221.37 | 173.90 |
| Year-End Price | 358.17 | 516.42 | 326.04 | 264.79 | 194.91 | 241.88 | 173.90 |
SARTORIUS STED BIO passes 3 of 9 quality checks, indicating weak fundamentals.
SARTORIUS STED BIO trades at 56.3x trailing earnings, compared to its 15-year median P/E of 82.0x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 21.6x vs a median of 38.6x. The company's 5-year average ROIC is 13.1% with a gross margin of 47.8%. Total shareholder yield (dividends) is 0.4%. At current prices, the estimated annualized return to fair value is +10.4%.
SARTORIUS STED BIO (DIM-PA) has a current P/E ratio of 56.3, compared to its historical median P/E of 82.0. The stock is currently considered Cheap based on its historical valuation range.
SARTORIUS STED BIO (DIM-PA) has a 5-year average return on invested capital (ROIC) of 13.1%. This indicates solid capital allocation.
SARTORIUS STED BIO (DIM-PA) has a market capitalization of $16.9B. It is classified as a large-cap stock.
Yes, SARTORIUS STED BIO (DIM-PA) pays a dividend with a trailing twelve-month yield of 0.45%.
Based on historical P/E analysis, SARTORIUS STED BIO (DIM-PA) appears cheap. The current P/E of 56.3 is 31% below its historical median of 82.0. The estimated fair value CAGR (P/E method) is -4.9%.
SARTORIUS STED BIO (DIM-PA) operates in the Medical - Instruments & Supplies industry, within the Healthcare sector.
SARTORIUS STED BIO (DIM-PA) reported annual revenue of $3.4 billion in its most recent fiscal year, based on SEC EDGAR filings.
SARTORIUS STED BIO (DIM-PA) has a net profit margin of 9.0%. This is a modest margin.
SARTORIUS STED BIO (DIM-PA) generated $784 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
SARTORIUS STED BIO (DIM-PA) has a debt-to-equity ratio of 0.59. This indicates moderate leverage.
SARTORIUS STED BIO (DIM-PA) reported earnings per share (EPS) of $3.09 in its most recent fiscal year.
SARTORIUS STED BIO (DIM-PA) has a return on equity (ROE) of 6.7%. This indicates moderate shareholder returns.
SARTORIUS STED BIO (DIM-PA) has a 5-year average gross margin of 47.8%. This indicates decent pricing power.
The Ledger Terminal provides 6 years of financial data for SARTORIUS STED BIO (DIM-PA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SARTORIUS STED BIO (DIM-PA) has a book value per share of $47.60, based on its most recent annual SEC filing.
No recent press releases.